Px Wire
Px
Wire is AVAC's quarterly update on
biomedical HIV prevention research. Each issue
includes a comprehensive time line of ongoing
efficacy trials around the world and a map
showing where these trials are happening. Each
issue also includes updates on news, emerging
issues and upcoming events.

The latest issue is available as a PDF and as a webpage.
![]()

Download graphics from the latest issue of Px Wire:
- Map of Ongoing HIV Prevention Research Trials (PDF, JPG, PPT)
- Timeline of HIV Prevention Efficacy and Follow-on Trial Results (PDF, JPG, PPT)
Px Wire Archive: View Px Wire issues starting from January 2008
January-March, Volume 5, Number
1
To start off the issue, we identify 10 key
outcomes to pursue in order to make progress in
beginning to end the AIDS epidemic. This issue
also covers:
- Gilead Science’s submission to FDA for a label change for TDF/FTC (brand name Truvada) indicating that it can be used as HIV prevention in HIV-negative adults.
- The closure of the 1% tenofovir gel arm of the VOICE trial, which is evaluating oral and topical tenofovir-based PrEP—and a review of other key trials of tenofovir gel.
- New trials launched this quarter including the French IPERGAY pilot for an efficacy trial of coitally-related oral PrEP using TDF/FTC in MSM.
- The first meeting of Project ARM (Africa for Rectal Microbicides)—a new civil society initiative focused on rectal microbicides research and anal health.
The latest issue is available as a PDF and as a webpage.
Download graphics from the latest issue of Px Wire:
- Map of Ongoing HIV Prevention Research Trials (PDF, JPG, PPT)
- Timeline of HIV Prevention Efficacy and Follow-on Trial Results (PDF, JPG, PPT)
Px Wire Archive: View Px Wire issues starting from January 2008




